Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 1;31(1):17-22.
doi: 10.1200/JCO.2012.43.1718. Epub 2012 Nov 5.

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

Michael J Overman  1 , Janhavi Modak, Scott Kopetz, Ravi Murthy, James C Yao, Marshall E Hicks, James L Abbruzzese, Alda L Tam
Affiliations

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

Michael J Overman et al. J Clin Oncol. .

Abstract

Purpose: Although the incorporation of research biopsies into clinical trials is increasing, limited information is available about how study protocols and informed consents integrate and describe their use.

Methods: All therapeutic clinical trials in which image-guided research biopsies were performed from January 1, 2005, to October 1, 2010, were identified from an interventional radiology database. Data from study protocols and informed consents were extracted and analyzed. Procedural complications were recorded.

Results: A total of 57 clinical trials were identified, of which 38 (67%) contained at least one mandatory biopsy. The analysis of the research biopsy tumor tissue was a study end point in 95% of trials. The primary indication for a research biopsy was for integral biomarker analysis in 32% and for correlative science in 68% of trials. A statistical analytic plan for the correlative science research biopsy tumor tissue was mentioned in 26%, described as exploratory in 51%, and not mentioned in 23% of trials. For studies with mandatory biopsies, biopsy was an eligibility criterion in 71% of trials, and a statistical justification for the research biopsy sample size was present in 50% of trials. A total of 745 research biopsies were performed on 576 patients. Overall and major complication rates were 5.2% (39 of 745 biopsies) and 0.8% (six of 745 biopsies), respectively. Complication rates for intrathoracic and abdominal/pelvic solid organ biopsies were 17.1% (36 of 211 biopsies) and 1.6% (three of 189 biopsies), respectively. Site-stratified research biopsy-related risks were discussed in five consents.

Conclusion: A better representation of the risks and benefits of research biopsies in study protocols and informed consents is needed.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Banerji U de Bono J Judson I, etal: Biomarkers in early clinical trials: The committed and the skeptics Clin Cancer Res 14:2512,2008author reply 2513-2514 - PubMed
    1. Cannistra SA: Performance of biopsies in clinical research J Clin Oncol 25:1454–1455,2007 - PubMed
    1. Goulart BH Clark JW Pien HH, etal: Trends in the use and role of biomarkers in phase I oncology trials Clin Cancer Res 13:6719–6726,2007 - PubMed
    1. Helft PR, Daugherty CK: Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation J Clin Oncol 24:4793–4795,2006 - PubMed
    1. Joffe S, Miller FG: Bench to bedside: Mapping the moral terrain of clinical research Hastings Cent Rep 38:30–42,2008 - PubMed